Pharmaceuticals 2010, 3(9), 2884-2899; https://doi.org/10.3390/ph3092884
Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
Icagen, Inc., 4222 Emperor Blvd, Durham, NC 27703, USA
*
Author to whom correspondence should be addressed.
Received: 19 August 2010 / Revised: 25 August 2010 / Accepted: 1 September 2010 / Published: 1 September 2010
Abstract
Current marketed antiepileptic drugs (AEDs) consist of a variety of structural classes with different mechanisms of action. These agents typically have non-overlapping efficacy and side-effect profiles presenting multiple treatment options for the patient population. However, approximately 30% of seizure sufferers fail to respond to current therapies often because poorly tolerated side-effects limit adequate dosing. The scope of this review is to summarize selected advances in 2nd and 3rd generation AEDs as well as compounds in development with novel mechanisms of action. View Full-TextKeywords:
epilepsy; antiepileptic; AED; seizure; anticonvulsant
▼
Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Gerlach, A.C.; Krajewski, J.L. Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going? Pharmaceuticals 2010, 3, 2884-2899.
Related Articles
Article Metrics
Comments
[Return to top]
Pharmaceuticals
EISSN 1424-8247
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert